The Trump administration aims to finalize Medicare pilot programs called GLOBE and GUARD, which require biotech firms to rebate the federal government based on the price difference between their drug prices abroad and what Medicare pays in the U.S. This initiative is intended to reduce global pricing disparities that disproportionately fund American research and development. However, critics argue this approach overlooks that small and mid-size biotechs often out-license drugs to larger companies for international sales, leaving these smaller firms with little control over foreign pricing decisions or ability to recover costs from partners. As a result, the proposal could hurt U.S. innovators by discouraging such licensing agreements essential for funding research and development.
Written locally by qwen2.5:14b on 2026-09-21,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
The Trump administration wants American biotech companies to play hardball with foreign health systems — and stop giving special discounts that aren’t offered here at home.
asserted
that → want → home
To that end, the White House is moving to finalize two Medicare pilot programs, “GLOBE” and “GUARD.”
asserted
House → move → programs
Both would require biotech firms to send rebates to the federal government, determined by the difference between the foreign prices of their drugs and the prices that Medicare pays.
asserted
Medicare → require → that
In theory, the prospect of cutting big rebates to Medicare would force biotech firms to eliminate the pricing disparities by charging significantly more abroad.
asserted
prospect → cut → more
Americans would no longer have to disproportionately fund research and development that benefits the entire world.
asserted
that → have → world
But there’s an overlooked aspect of these GLOBE and GUARD proposals that could undermine that logic and hurt U.S. innovators and biotech companies — many of these companies can’t drive a harder bargain.
uncertain
many → ’ → bargain
The reason is straightforward, but little-known outside the biotech industry.
asserted
reason → know → industry
They originate over half of FDA-approved drugs.
asserted
They → originate → drugs
But these firms often have just a few dozen employees.
asserted
firms → have → employees
Navigating the long and costly research and development process, and later the FDA approval process, is incredibly challenging.
asserted
Navigating → navigate → process
Figuring out how to manufacture their drug at scale and launch it in the United States is even more daunting.
asserted
Figuring → figure → States
And simultaneously launching that same drug in France, Germany, and dozens of other developed countries — which all have different legal and healthcare systems — is far beyond most small firms’ capabilities.
asserted
which → launch → capabilities
That’s why U.S. biotechs frequently strike “outlicensing” agreements with larger companies.
asserted
biotechs → ’ → companies
The small biotech generally retains the underlying intellectual property and the right to market the medicine in the United States.
asserted
biotech → retain → States
The larger company receives the right to sell the drug in foreign markets.
asserted
company → receive → markets
In exchange, that larger company pays an upfront fee and perhaps ongoing royalty payments, which smaller companies can then use to fund their research efforts.
asserted
companies → pay → efforts
It’s a mutually beneficial arrangement that underpins much of biotech innovation today.
asserted
that → ’ → innovation
But when companies out-license their medicines, they generally hand off marketing and sales rights to the partner company.
asserted
they → license → company
Biotech companies generally have little to no contractual authority over pricing decisions or visibility into relevant pricing information.
asserted
companies → have → information
Antitrust and competition laws may also make it challenging to share pricing information between the biotech company and its licensing partners.
uncertain
it → make → company
And that’s a central flaw in proposals like GLOBE and GUARD.
asserted
that → ’ → GLOBE
These frameworks impose costs that small biotechs have little ability to prevent or recover, placing an outsized burden on some of the industry’s most resource-constrained innovators.
asserted
biotechs → impose → innovators
If the government effectively penalizes outlicensing, companies would be forced to stop pursuing these agreements, and potential partners would become increasingly reluctant to enter into them.
asserted
partners → penalize → them
That would deprive companies of those upfront payments and royalties, as well as diminish investor confidence and reduce companies’ valuations — key sources of capital that support continued research into breakthrough cures and medicines.
asserted
that → deprive → cures
Some could be forced to scale back clinical trials, abandon promising treatments, or shut down altogether.
uncertain
Some → force → treatments
Patients would ultimately pay the price, as fewer lifesaving medicines reach the market both here and abroad — and those that do face significant delays or fall short of their full potential.
asserted
that → pay → potential
The policy would also undermine America’s global leadership in biotechnology.
asserted
policy → undermine → biotechnology
At a time when China is investing heavily in medical innovation, the United States should be making it easier for homegrown biotech companies to invent and commercialize therapies — not penalizing one of the financial arrangements that allows innovators to survive.
asserted
innovators → invest → arrangements
Foreign governments’ demands for heavy drug discounts unfairly burden American patients and taxpayers.
asserted
demands → burden → patients
But GLOBE and GUARD target the wrong culprit.
asserted
GLOBE → target → culprit
American biotechs can’t negotiate more aggressively with foreign governments when they’re not a party to those negotiations in the first place.
asserted
they → negotiate → place
So if the administration wants to end foreign freeriding, it’ll need to take on those freeloading governments directly.
asserted
it → want → governments
The Aporia
